Clinical Trials

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

46 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05983965 2025-09-10

Study of Tazemetostat in Lymphoid Malignancies

30 enrolled

Leukemia, Lymphoma, Lymphoma, T-Cell

NCT03240211 2025-08-26

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

37 enrolled

Lymphoma, T-Cell

NCT05290155 2025-06-06

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

14 enrolled

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02783625 2025-06-03

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

114 enrolled

Lymphoma, Lymphoma, T-Cell

NCT06547528 2025-06-03

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

108 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell

NCT06699771 2025-04-30

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

48 enrolled

Lymphoma, T-Cell

NCT05377827 2025-04-29

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

6 enrolled

Immunoblastic Lymphadenopathy, Sezary Syndrome, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03952078 2025-04-16

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

151 enrolled

Lymphoma, T-Cell

NCT02342782 2025-03-20

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

5 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04502446 2025-01-08

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Phase 1 Terminated

49 enrolled

Lymphoma, Lymphoma, T-Cell

NCT04136275 2024-12-12

CAR-37 T Cells in Hematologic Malignancies

6 enrolled

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

54 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06696846 2024-11-20

CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

Phase 1 Not yet recruiting

25 enrolled

Leukemia, Myeloid, Acute, Lymphoma, T-Cell

NCT05984147 2024-01-31

ASHA-1

40 enrolled

Lymphoma, Follicular, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03833180 2024-01-12

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

91 enrolled

Burkitt Lymphoma, Leukemia, Leukemia, Lymphoid, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04712864 2023-10-03

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

50 enrolled

Lymphoma, T-Cell

NCT02309580 2023-05-09

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

14 enrolled

Recurrence, Lymphoma, T-Cell

NCT05557903 2022-09-28

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

71 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT03905135 2022-09-13

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

8 enrolled 18 charts

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04219319 2022-08-16

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

Phase 1 Terminated

4 enrolled

Leukemia, T-Cell, Lymphoma, T-Cell

NCT04973527 2022-08-16

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

Phase 1 Terminated

9 enrolled

Leukemia, T-Cell, Lymphoma, T-Cell

NCT05387226 2022-05-24

Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma

6 enrolled

Virus Diseases, Lymphoma, T-Cell

NCT04823091 2022-03-16

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

24 enrolled

Leukemia, T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell

NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

15 enrolled 18 charts

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT03263637 2021-10-22

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies